Vaginal Misoprostol Prior to Intrauterine Contraceptive Device Insertion in Women Who Delivered Only By Elective Caeserean Section: Randomized Clinical Trial

N. Sakna, M. A. N. A. Gawad, Enas Elshahid, Ahmed Atik
{"title":"Vaginal Misoprostol Prior to Intrauterine Contraceptive Device Insertion in Women Who Delivered Only By Elective Caeserean Section: Randomized Clinical Trial","authors":"N. Sakna, M. A. N. A. Gawad, Enas Elshahid, Ahmed Atik","doi":"10.21608/ebwhj.2020.26232.1082","DOIUrl":null,"url":null,"abstract":"Background: Intrauterine contraceptive devices (IUCDs) are one of the reversible effective contraceptives. However its use is limited by the high cost in some settings and fear of pain at insertion time. Objectives: The aim of the study was to evaluate the role of vaginal misoprostol (400microgram) administration 3h prior to intrauterine contraceptive device (IUCD) insertion in women delivered only by elective caesarean section.Patients and Methods: A double-blind randomised controlled trial was conducted in 210 women who were eligible for IUD insertion. Participants were randomly divided to receive either 400 microgram vaginal misoprostol or placebo 3h before IUD insertion. The primary outcome measure was insertion difficulty score. Secondary outcome measures were the pain score during the procedur, complications of IUD insertion and side effects related to misoprostol. Results: Insertion difficulty and pain scores were significantly lower in the misoprostol group compared with the placebo group ( 89 [84.8%] vs. 41 [39.0%]; p < 0.001 and 1.3±0.6 vs. 2.5±1.2; p < 0.001 respectively). More women experienced nausea, vomiting (10 vs. 0; p < 0.001) and shievering (6 vs. 0; p < 0.029) in the misoprostol group than in the placebo group, respectively. Conclusion: The study concluded that using of misoprostol at a dose of 400 microgram administered vaginally 3 hours prior to IUCD insertion in women who delivered only by elective cesarean section had significant effect on increase easiness of insertion and reduce the incidence of pain during the procedure.","PeriodicalId":224226,"journal":{"name":"Evidence Based Womenʼs Health Journal","volume":"9 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence Based Womenʼs Health Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/ebwhj.2020.26232.1082","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Intrauterine contraceptive devices (IUCDs) are one of the reversible effective contraceptives. However its use is limited by the high cost in some settings and fear of pain at insertion time. Objectives: The aim of the study was to evaluate the role of vaginal misoprostol (400microgram) administration 3h prior to intrauterine contraceptive device (IUCD) insertion in women delivered only by elective caesarean section.Patients and Methods: A double-blind randomised controlled trial was conducted in 210 women who were eligible for IUD insertion. Participants were randomly divided to receive either 400 microgram vaginal misoprostol or placebo 3h before IUD insertion. The primary outcome measure was insertion difficulty score. Secondary outcome measures were the pain score during the procedur, complications of IUD insertion and side effects related to misoprostol. Results: Insertion difficulty and pain scores were significantly lower in the misoprostol group compared with the placebo group ( 89 [84.8%] vs. 41 [39.0%]; p < 0.001 and 1.3±0.6 vs. 2.5±1.2; p < 0.001 respectively). More women experienced nausea, vomiting (10 vs. 0; p < 0.001) and shievering (6 vs. 0; p < 0.029) in the misoprostol group than in the placebo group, respectively. Conclusion: The study concluded that using of misoprostol at a dose of 400 microgram administered vaginally 3 hours prior to IUCD insertion in women who delivered only by elective cesarean section had significant effect on increase easiness of insertion and reduce the incidence of pain during the procedure.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
仅择期剖宫产的妇女在插入宫内节育器前使用阴道米索前列醇:随机临床试验
背景:宫内节育器(IUCDs)是一种可逆的有效避孕方法。然而,在某些情况下,它的使用受到高成本和插入时对疼痛的恐惧的限制。目的:本研究的目的是评估米索前列醇(400微克)阴道给药前3h的宫内节育器(IUCD)插入妇女只分娩择期剖宫产。患者和方法:对210例符合宫内节育器置入条件的妇女进行双盲随机对照试验。参与者在宫内节育器插入前3小时随机分为400微克阴道米索前列醇组和安慰剂组。主要结局指标为插入难度评分。次要观察指标为术中疼痛评分、宫内节育器植入并发症及米索前列醇相关副作用。结果:米索前列醇组插入困难和疼痛评分明显低于安慰剂组(89分[84.8%]比41分[39.0%];P < 0.001和1.3±0.6 vs. 2.5±1.2;P < 0.001)。更多的女性出现恶心、呕吐(10比0;P < 0.001)和颤抖(6 vs. 0;P < 0.029),米索前列醇组与安慰剂组比较差异有统计学意义。结论:仅择期剖宫产分娩的妇女在宫内节育器置入前3小时阴道给予米索前列醇400微克,对增加宫内节育器置入的容易程度和减少术中疼痛发生率有显著效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Hysteroscopy as a diagnostic tool in women with recurrent pregnancy loss, a prospective randomized controlled study Serum Soluble Endoglin Versus Serum Placental Growth Factor for Early Prediction of Preeclampsia Cervical cerclage for Pregnant Women at High-risk of Recurrent Preterm Birth can act beyond its Mechanical Action New ultrasound signs for prediction of early placental Insufficiency Efficacy and Safety of Preoperative Intravenous Tranexamic Acid to Reduce Blood Loss During and After Elective Lower‐Segment Cesarean Delivery
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1